by 
The global Acute Bacterial Skin and Skin Structure Infections market comprises various treatment options for preventing acute bacterial skin infections by combating drug-resistant bacterial strains. The leading treatment types available in the market are beta-lactam and beta-lactamase inhibitors, quinolones, macrolides, and tetracyclines. beta-lactam and beta-lactamase inhibitors are highly effective against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Quinolones have broad-spectrum antibacterial activity and are commonly used as an alternative to beta-lactams in cases where patients have immediate hypersensitivity to penicillin. Macrolides are prescribed for mild to moderate skin infections and act by inhibiting protein synthesis in bacteria. Tetracyclines demonstrate activity against a wide range of Gram-positive and Gram-negative bacteria making them a preferred choice.
The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the Acute Bacterial Skin and Skin Structure Infections market is the rising occurrence of antimicrobial resistance. Several bacterial strains have developed resistance against commonly used antibiotics due to the indiscriminate use and misuse of antibiotics. According to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health. It is estimated that drug-resistant diseases could cause 10 million deaths each year by 2050. This alarming rise in antibiotic resistance is augmenting research and development of newer drugs to effectively treat acute bacterial skin infections. Companies in the market are investing heavily in developing novel antibacterial drugs with new mechanisms of action to overcome resistance issues.
Porter’s Analysis
Threat of new entrants: The acute bacterial skin and skin structure infections market requires high R&D investments and regulatory approvals, lowering the threat of new entrants.
Bargaining power of buyers: The presence of many established players makes it difficult for buyers to bargain on prices. However, availability of generic alternatives provides some bargaining power.
Bargaining power of suppliers: Established players have a significant influence on suppliers due to their large procurement volumes and economies of scale.
Threat of new substitutes: Alternatives like local antibiotic treatments offer some level of substitution.
Competitive rivalry: The market sees intense competition due to many global and regional players offering generic and branded drugs.
Key Takeaways
The global Acute Bacterial Skin and Skin Structure Infections market is expected to witness high growth.
Regional Analysis: North America currently dominates the market owing to latest technology adoption and higher healthcare spending. However, Asia Pacific is expected to grow at the fastest pace during the forecast period with increasing patient pool and healthcare infrastructure development.
Key players operating in the Acute Bacterial Skin and Skin Structure Infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. The market is moderately consolidated with top players focusing on new product development through R&D.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
